Research article · 27 Oct 2023
Conference abstractPublished 19 Dec 2014
H2S-based drug development and delivery
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
More than a toxin generated in chemistry industry and from environmental pollution, hydrogen sulfide (H2S) is also produced in our bodies with L-cysteine and homocysteine as the endogenous substrate. Over the last decade, the physiological importance of H2S has been demonstrated in numerous human body systems, including the cardiovascular and respiratory, neuronal, endocrinal, gastrointestinal, reproductive, liver, kidney and urinary systems. Altered metabolism and functions of H2S constitutes a critical factor for the pathogenesis of a number of human diseases, such as hypertension, atherosclerosis, heart failure and stroke, diabetes, asthma, neurodegenerative diseases, gastrointestinal inflammation, cancer, etc. In recent years, multiple lines of H2S-based drugs (organic and inorganic H2S-donors or hybrid molecules) have been developed for different clinical situations. Fast-releasing H2S donors, such as NaHS and Na2S, offer the tool to quickly correct H2S deficiency under specific pathological conditions, e.g. ischemic/reperfusion heart failure. Slow-releasing H2S donors, such as GYY4137, provide sustained protection against H2S-related chronic diseases. Mitochondria-targeted H2S donors, such as AP39, have the potential to directly optimize mitochondrial energy production and oxidant/antioxidant balance. These novel approaches have been successful in animal studies and being tested clinically at different trial stages. With improved delivery methods and organ- and cell type-specific releasing mechanism for H2S release, H2S-based drug development opens new horizon for improving the efficiency and potency, decreasing the side effect, minimizing the disturbance of system homeostasis of the next generation of drugs. (Supported by an operating grant from Canadian Institutes of Health Research)
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 28 Sep 2018
Transdermal delivery of pravastatin loaded microemulsion based drug delivery system developed by central composite design
Conference abstract · 24 Sep 2018
Transdermal delivery of Pravastatin loaded microemulsion based drug delivery system developed by central composite design
Conference abstract · 25 Sep 2017
Development of gastro-retentive drug delivery systems based on N-isopropyl acrylamide hydrogels
Conference abstract · 30 Jun 2016
Development, physicochemical and cytotoxic evaluation of polymeric nanocarriers for dual delivery of metal-based anticancer drugs and potentiating agents
More from this journal
The newest in Clinical Pharmacology & Biopharmaceutics.
Research article · 27 Jul 2026
Qualitative LC/MS Assessment of Fenfluramine Hydrochloride After Dilution in Purified Water : A Preliminary Study and Case Report
Article · 20 Jul 2026
Population Pharmacology: Precision Dosing for Diverse Patients
Article · 17 Jul 2026
Therapeutic Drug Monitoring: Optimizing Therapy, Minimizing Toxicity
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical Pharmacology & Biopharmaceutics
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Rui Wang”
